Hans–Henrik Tilsted

Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial

Thomas Engstrøm, Henning Kelbæk, Steffen Helqvist et al. · The Lancet · 2015 · 966 citations

Medicine, Cardiology, Internal Medicine +16

Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study

David Erlinge, Akiko Maehara, Ori Ben‐Yehuda et al. · The Lancet · 2021 · 477 citations · Full text

Medicine, Cardiology, Diagnostic Imaging +16

Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial

Henning Kelbæk, Dan Eik Høfsten, Lars Køber et al. · The Lancet · 2016 · 206 citations

Medicine, Cardiology, Clinical Cardiology +11

Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial

Evald Høj Christiansen, Lisette Okkels Jensen, Per Thayssen et al. · The Lancet · 2013 · 203 citations · Full text

Medicine, Cardiology, Clinical Cardiology +14

Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention

Lisette Okkels Jensen, Per Thayssen, Jan Ravkilde et al. · Circulation Cardiovascular Interventions · 2016 · 128 citations · Full text

Medicine, Cardiology, Biomaterials +15